A phase II trial assessed the safety and efficacy of pembrolizumab, gemcitabine, vinorelbine, and liposomal doxorubicin (pembrolizumab-GVD) in transplant-eligible patients with relapsed/refractory (rel/rel) cHL, and demonstrated a complete response (CR) rate of 95% and progression-free survival (PFS) of 100% at 13.5 mo...
K. Patel, G. Shah, H. Schöder et al.· Blood· 0 citations
BACKGROUND
Infectious complications are a major cause of morbidity and non-relapse mortality after CAR-T cell therapy. Respiratory viral infections (RVIs) are frequent, yet their incidence, timing, and immune correlates remain incompletely defined.
METHODS
We retrospectively analyzed laboratory-confirmed RVIs in 563...
S. Einarsdottir, Teng Fei, M. Sotelo-Alva et al.· International Journal of Inf...· 0 citations
It remains uncertain whether lower CD19 expression is clinically relevant for outcomes of CD19 CAR-T therapy of large B-cell lymphoma (LBCL). We conducted an integrative analysis of tumor CD19 levels with centralized quantitative assessment by flow cytometry (FC), immunohistochemistry and RNA-sequencing in a LBCL cohor...
M. Corona, Aaron Gillmor, K. Argyropoulos et al.· Blood Cancer Discovery· 0 citations
The overall response rate was 95% (95% CI 84-99; 39 of 41 patients), and the most common grade 3-4 adverse events were neutropenia and infections, while epcoritamab showed high activity in first-line treatment for follicular lymphoma.
L. Falchi, J. Vermaat, Joshua D. Brody et al.· The Lancet Haematology· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
